Trial Profile
A randomised, controlled, comparative, open-label, multicenter study on the safety and efficacy of PEG Neutrogen and Neulastim in prevention of chemotherapy-induced neutropenia
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Nov 2020
Price :
$35
*
At a glance
- Drugs Pegfilgrastim (Primary)
- Indications Neutropenia
- Focus Therapeutic Use
- Sponsors Virchow Group
- 04 Nov 2020 Status changed from not yet recruiting to completed.
- 22 Jun 2018 New trial record